Refine
Year of publication
Has Fulltext
- yes (42)
Is part of the Bibliography
- no (42)
Keywords
- HNSCC (3)
- Penile carcinomas (3)
- Radiotherapy (3)
- Breast cancer (2)
- Diagnostik (2)
- Früherkennung (2)
- Head and neck cancer (2)
- Mammakarzinom (2)
- Nachsorge (2)
- PD-L1 (2)
- Patterns of care (2)
- Richtlinie (2)
- Tumor microenvironment (2)
- breast cancer (2)
- diagnosis (2)
- follow‑up (2)
- guideline (2)
- prostate cancer (2)
- screening (2)
- Advanced breast cancer (1)
- Anal cancer (1)
- Anterior cingulate cortex (1)
- Antibodies (1)
- Antihormone therapy (1)
- Biomarker (1)
- Brain metastasis (1)
- CD8+ tumor infiltrating lymphocytes (1)
- COVID-19 (1)
- CUP (1)
- Cancer of unknown primary (1)
- Cancer treatment (1)
- Central nervous system metastases (1)
- Cervical (1)
- Chemoradiotherapy (1)
- Clinical Trials and Observations (1)
- D’Amico classification (1)
- EGFR (1)
- Emotion (1)
- Empathy (1)
- FDG-PET/CT (1)
- First site of metastatic disease (1)
- Gleason score (1)
- HER2 c-erbB2 (1)
- HER2/neu (1)
- HIV (1)
- HPV infection (1)
- HPV-positive OPSCC (1)
- Head neck cancer (1)
- Heregulin (1)
- Immunology (1)
- Immunophenotyping (1)
- Immunotherapy (1)
- Imrt (1)
- Induction therapy (1)
- Juvenile myoclonic epilepsy (1)
- LCD-Array (1)
- Lee-type (1)
- Lesions (1)
- Loco-regional control (1)
- Lymph node (1)
- Lymphocyte subpopulations (1)
- Lymphoid Neoplasia (1)
- MM-121 (1)
- Machine learning (1)
- Metastatic (1)
- Molecular diagnostics (1)
- NK cell subsets (1)
- Necrosis (1)
- Non-small cell lung cancer (1)
- Oncology (1)
- Prediction of locoregional recurrence (1)
- Pupillometry (1)
- Radiation Oncology (1)
- Radiochemotherapy (1)
- Radiomics (1)
- Real-time polymerase chain reaction (PCR) tests (1)
- SARS-CoV-2 testing (1)
- SCCHN (1)
- SELEX (1)
- Salivary gland cancer (1)
- Salivary gland carcinoma (1)
- Sanger Sequencing (1)
- Screening (1)
- Seribantumab (1)
- Stereotactic ablative body radiotherapy (1)
- Stereotactic radiosurgery (1)
- Surgery (1)
- Survey (1)
- Survival (1)
- Systemic therapy (1)
- T-DM1 (1)
- TKI (1)
- Tissue microarray (1)
- Toxicity (1)
- Urological oncology (1)
- Validation (1)
- Viral infection (1)
- Viral oncology (1)
- activated factor XIII (1)
- advanced breast cancer (1)
- anal cancer (1)
- antibodies (1)
- antihormone therapy (1)
- apex (1)
- aptamer (1)
- aptamer modeling (1)
- b-cell lymphomas (1)
- bendamustine (1)
- cancer-specific survival (1)
- caspase 8 (1)
- cervical cancer (1)
- cetuximab (1)
- chemoradiotherapy (1)
- chemotherapy (1)
- chemotherapy regimen (1)
- chimeric antigen receptor t-cell therapy (1)
- chimeric antigen receptors (1)
- combined modality therapy (1)
- diffusion-weighted magnetic resonance imaging (1)
- double immune checkpoint inhibition (1)
- fMRI (1)
- functional outcome (1)
- gene signature (1)
- head and neck cancer (1)
- head and neck neoplasms (1)
- head and neck squamous cell carcinoma (1)
- hematopoietic stem cell transplantation (1)
- image-based risk modelling (1)
- immune-checkpoint inhibition (1)
- immunotherapy (1)
- induction therapy (1)
- inverse stage migration (1)
- lapatinib (1)
- leukapheresis (1)
- leukopenia (1)
- local control (1)
- lymphoma (1)
- mTOR (1)
- machine learning (1)
- membranous urethra (1)
- merkel cell carcinoma (1)
- metastatic (1)
- mid-term urinary continence (1)
- multiplexed immunofluorescence (1)
- neoadjuvant chemoradiotherapy (1)
- nucleic acid docking (1)
- oral cavity cancer (1)
- organ preservation (1)
- outcome (1)
- overall survival (1)
- p16 (1)
- personalised therapy (1)
- pertuzumab (1)
- polo-like kinase 3 (1)
- polyomavirus (MCPyV) (1)
- postoperative radiochemotherapy (1)
- postoperative radiotherapy (1)
- predictive biomarker (1)
- propensity score matching (1)
- radiation oncology (1)
- radical prostatecomy (1)
- radical prostatectomy (1)
- radioimmunotherpay (1)
- radiomic (1)
- re-irradiation (1)
- rituximab (1)
- sarcopenia (1)
- targeted therapy (1)
- thrombopenia (1)
- toxicity (1)
- transglutaminase (1)
- trastuzumab (1)
Institute
- Medizin (42) (remove)
Emotional instability, difficulties in social adjustment, and disinhibited behavior are the most common symptoms of the psychiatric comorbidities in juvenile myoclonic epilepsy (JME). This psychopathology has been associated with dysfunctions of mesial-frontal brain circuits. The present work is a first direct test of this link and adapted a paradigm for probing frontal circuits during empathy for pain. Neural and psychophysiological parameters of pain empathy were assessed by combining functional magnetic resonance imaging (fMRI) with simultaneous pupillometry in 15 JME patients and 15 matched healthy controls. In JME patients, we observed reduced neural activation of the anterior cingulate cortex (ACC), the anterior insula (AI), and the ventrolateral prefrontal cortex (VLPFC). This modulation was paralleled by reduced pupil dilation during empathy for pain in patients. At the same time, pupil dilation was positively related to neural activity of the ACC, AI, and VLPFC. In JME patients, the ACC additionally showed reduced functional connectivity with the primary and secondary somatosensory cortex, areas fundamentally implicated in processing the somatic cause of another's pain. Our results provide first evidence that alterations of mesial-frontal circuits directly affect psychosocial functioning in JME patients and draw a link of pupil dynamics with brain activity during emotional processing. The findings of reduced pain empathy related activation of the ACC and AI and aberrant functional integration of the ACC with somatosensory cortex areas provide further evidence for this network's role in social behavior and helps explaining the JME psychopathology and patients' difficulties in social adjustment.
Background: To study neoadjuvant chemoradiotherapy (nCRT) and potential predictive factors for response in locally advanced oral cavity cancer (LA-OCC).
Methods: The INVERT trial is an ongoing single-center, prospective phase 2, proof-of-principle trial. Operable patients with stage III-IVA squamous cell carcinomas of the oral cavity were eligible and received nCRT consisting of 60 Gy with concomitant cisplatin and 5-fluorouracil. Surgery was scheduled 6-8 weeks after completion of nCRT. Explorative, multiplex immunohistochemistry (IHC) was performed on pretreatment tumor specimen, and diffusion-weighted magnetic resonance imaging (DW-MRI) was conducted prior to, during nCRT (day 15), and before surgery to identify potential predictive biomarkers and imaging features. Primary endpoint was the pathological complete response (pCR) rate.
Results: Seventeen patients with stage IVA OCC were included in this interim analysis. All patients completed nCRT. One patient died from pneumonia 10 weeks after nCRT before surgery. Complete tumor resection (R0) was achieved in 16/17 patients, of whom 7 (41%, 95% CI: 18-67%) showed pCR. According to the Clavien-Dindo classification, grade 3a and 3b complications were found in 4 (25%) and 5 (31%) patients, respectively; grade 4-5 complications did not occur. Increased changes in the apparent diffusion coefficient signal intensities between MRI at day 15 of nCRT and before surgery were associated with better response (p=0.022). Higher abundances of programmed cell death protein 1 (PD1) positive cytotoxic T-cells (p=0.012), PD1+ macrophages (p=0.046), and cancer-associated fibroblasts (CAFs, p=0.036) were associated with incomplete response to nCRT.
Conclusion: nCRT for LA-OCC followed by radical surgery is feasible and shows high response rates. Larger patient cohorts from randomized trials are needed to further investigate nCRT and predictive biomarkers such as changes in DW-MRI signal intensities, tumor infiltrating immune cells, and CAFs.